Back to today’s briefing

Story perspectives

FDA Approves Generic Mifepristone Amid Abortion Debate

10/3/2025

27 2 Full Breakdown

Summary

Story summary

The FDA approved a generic version of mifepristone, enabling three companies to produce it amid anti-abortion pressure.
The approval follows the Supreme Court's 2022 ruling overturning the national right to abortion.
Critics, including anti-abortion leaders, condemn the decision as undermining safety and access rules. Supporters cite evidence and safety record.
The new generic is expected to arrive in January 2026.

History

Historical Context

The 1973 Supreme Court decision Roe v. Wade legalized abortion in the U.S., establishing a constitutional right that shaped reproductive rights. In 2000, the FDA approved mifepristone for medical abortions. Following the 2022 Supreme Court ruling that overturned Roe v. Wade, the recent FDA approval of a generic mifepristone may enhance access to abortion medications amid ongoing opposition from anti-abortion advocates.

1 of 2

Story summary

The FDA approved a generic version of mifepristone, enabling three companies to produce it amid anti-abortion pressure.
The approval follows the Supreme Court's 2022 ruling overturning the national right to abortion.
Critics, including anti-abortion leaders, condemn the decision as undermining safety and access rules. Supporters cite evidence and safety record.
The new generic is expected to arrive in January 2026.

1 / 2